Skip to main content

Ishara Investments LP

SEC CIK
0002111609
Latest filing
Aug 14, 2026

The latest 13F from Ishara Investments LP covers Q2 2026 (filed Aug 14, 2026): 41 long positions worth $133.7M. The top 10 holdings make up 51.9% of the portfolio, and the largest is Acadia Pharmaceuticals Inc (ACAD) at 7.8%. Livermore has 3 filings on Form 13F from this institution, going back to Q4 2025.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
16
Est. +$43.4M
Added
13
Est. +$24.0M
Reduced
8
Est. −$15.0M
Sold out
11
Est. −$31.4M

Top 5 holdings

Share of this quarter's portfolio value

  1. ACADAcadia Pharmaceuticals Inc
    7.8%$10.4MHistory
  2. XERSXeris Biopharma Holdings, Inc.
    7.3%$9.74MHistory
  3. BMRNBiomarin Pharmaceutical Inc
    6.1%$8.21MHistory
  4. PRAXPraxis Precision Medicines, Inc.
    5.6%$7.55MHistory
  5. RAREUltragenyx Pharmaceutical Inc.
    5.1%$6.84MHistory

Share of portfolio

Top 5 holdings and the other 36 positions, by share of portfolio value

  1. ACAD7.8%
  2. XERS7.3%
  3. BMRN6.1%
  4. PRAX5.6%
  5. RARE5.1%
  6. Other 36 positions68.0%

Biggest buys

New and added positions, by estimated amount bought

  1. ACADAcadia Pharmaceuticals Inc
    +$7.26MAddedHistory
  2. AGIOAgios Pharmaceuticals, Inc.
    +$6.09MNewHistory
  3. INSMINSMED Inc
    +$5.46MNewHistory
  4. CRNXCrinetics Pharmaceuticals, Inc.
    +$5.37MNewHistory
  5. TNXPTonix Pharmaceuticals Holding Corp.
    +$4.32MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ACADAcadia Pharmaceuticals Inc
    +5.00 pp2.8% → 7.8%History
  2. AGIOAgios Pharmaceuticals, Inc.
    +4.55 pp0.0% → 4.6%History
  3. INSMINSMED Inc
    +4.09 pp0.0% → 4.1%History
  4. CRNXCrinetics Pharmaceuticals, Inc.
    +4.02 pp0.0% → 4.0%History
  5. TNXPTonix Pharmaceuticals Holding Corp.
    +3.23 pp0.0% → 3.2%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. AXSMAxsome Therapeutics, Inc.
    −$6.02MReducedHistory
  2. KALVKalVista Pharmaceuticals, Inc.
    −$5.57MSold outHistory
  3. FOLDAmicus Therapeutics, Inc.
    −$5.34MSold outHistory
  4. VSTMVerastem, Inc.
    −$4.35MSold outHistory
  5. ARWRArrowhead Pharmaceuticals, Inc.
    −$3.47MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. KALVKalVista Pharmaceuticals, Inc.
    −5.63 pp5.6% → 0.0%History
  2. FOLDAmicus Therapeutics, Inc.
    −5.39 pp5.4% → 0.0%History
  3. VSTMVerastem, Inc.
    −4.39 pp4.4% → 0.0%History
  4. AXSMAxsome Therapeutics, Inc.
    −4.00 pp7.0% → 3.0%History
  5. ARWRArrowhead Pharmaceuticals, Inc.
    −3.50 pp3.5% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$133.7M
+$34.6M (+35.0%) vs. prior quarter
Positions
41
+5 vs. prior quarter
Top 10 concentration
51.9%
Top 10 as share of value
Turnover
39.9%
Q2 2026, one quarter
Average holding period
2.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2025), so positions held before then are understated.

13F filings by quarter

3 quarters, going back to Q4 2025. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $133.7M (Q2 2026)

Q4 2025: $85.9MQ1 2026: $99.0MQ2 2026: $133.7M
Q4 2025Q2 2026
13F filings of Ishara Investments LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202641$133.7MACADXERSBMRNvs. Q1 2026SEC
Q1 2026May 15, 202636$99.0MPRAXAXSMXERSvs. Q4 2025SEC
Q4 2025Feb 17, 202637$85.9MPRAXXERSBMRN–SEC